124 related articles for article (PubMed ID: 12635473)
1. The economic burden of sepsis in Austria.
Schmid A; Schneider H
Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
[No Abstract] [Full Text] [Related]
2. [The incidence and cost of severe sepsis in intensive care units].
Csomós A; Hoffer G; Fülesdi B; Ludwig E
Orv Hetil; 2005 Jul; 146(29):1543-7. PubMed ID: 16136776
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of drotrecogin alfa (activated).
Tsitanidis J
Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
[No Abstract] [Full Text] [Related]
4. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?
Shorr AF; Micek ST; Jackson WL; Kollef MH
Crit Care Med; 2007 May; 35(5):1257-62. PubMed ID: 17414080
[TBL] [Abstract][Full Text] [Related]
5. Economics and outcome in the intensive care unit.
Pittoni GM; Scatto A
Curr Opin Anaesthesiol; 2009 Apr; 22(2):232-6. PubMed ID: 19390250
[TBL] [Abstract][Full Text] [Related]
6. Primary sepsis in a university hospital in northern Sweden: a retrospective study.
Jacobson S; Johansson G; Winsö O
Acta Anaesthesiol Scand; 2004 Sep; 48(8):960-7. PubMed ID: 15315612
[TBL] [Abstract][Full Text] [Related]
7. Cost of intensive care unit-acquired bloodstream infections.
Laupland KB; Lee H; Gregson DB; Manns BJ
J Hosp Infect; 2006 Jun; 63(2):124-32. PubMed ID: 16621137
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of activated protein C treatment for severe sepsis.
Manns BJ; Lee H; Doig CJ; Johnson D; Donaldson C
N Engl J Med; 2002 Sep; 347(13):993-1000. PubMed ID: 12324556
[TBL] [Abstract][Full Text] [Related]
9. Clinical imperative versus economic consequence: exploring the cost burden and opportunities in the care of patients with sepsis.
Merritt CL
Nurs Adm Q; 2011; 35(1):61-7. PubMed ID: 21157265
[TBL] [Abstract][Full Text] [Related]
10. [A method to determine hospital costs associated with nosocomial infections].
Gianino MM; Vallino A; Anselmo E; Minniti D; Abbona F; Mineccia C; Silvaplana P; Zotti CM
Ann Ig; 2007; 19(4):381-92. PubMed ID: 17937330
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
Chawla LS; Seneff MG; Nelson DR; Williams M; Levy H; Kimmel PL; Macias WL
Clin J Am Soc Nephrol; 2007 Jan; 2(1):22-30. PubMed ID: 17699383
[TBL] [Abstract][Full Text] [Related]
12. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.
Burchardi H; Schneider H
Pharmacoeconomics; 2004; 22(12):793-813. PubMed ID: 15294012
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
[TBL] [Abstract][Full Text] [Related]
14. Cost of bloodstream infections.
Kilgore M; Brossette S
Am J Infect Control; 2008 Dec; 36(10):S172.e1-3. PubMed ID: 19084149
[TBL] [Abstract][Full Text] [Related]
15. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysis.
Rosenthal VD; Guzman S; Migone O; Crnich CJ
Am J Infect Control; 2003 Dec; 31(8):475-80. PubMed ID: 14647110
[TBL] [Abstract][Full Text] [Related]
16. Cost evaluation of patients with severe sepsis in intensive care units.
Piacevoli Q; Palazzo F; Azzeri F
Minerva Anestesiol; 2004 Jun; 70(6):453-71. PubMed ID: 15235553
[No Abstract] [Full Text] [Related]
17. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
18. [Medical-economic evaluation of severe sepsis].
Guidet B
Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():28-30. PubMed ID: 15359937
[No Abstract] [Full Text] [Related]
19. [Exogenous activated protein C in severe sepsis].
Mamontova OA; Protsenko DN; Eliutin DV; Kirienko PN; Gel'fand BR
Anesteziol Reanimatol; 2005; (3):42-5. PubMed ID: 16076046
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates.
Tacconelli E; Smith G; Hieke K; Lafuma A; Bastide P
J Hosp Infect; 2009 Jun; 72(2):97-103. PubMed ID: 19246122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
